Corcept Therapeutics (NASDAQ: CORT) reported Q4 EPS of $0.77, versus $0.04 reported last year. Revenue for the quarter came in at $53.3 million, versus $23.8 million reported last year.

GUIDANCE:

Corcept Therapeutics sees FY2018 revenue of $275-300 million.

For earnings history and earnings-related data on Corcept Therapeutics (CORT) click here.